<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534261</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-BNL 99-01</org_study_id>
    <nct_id>NCT00534261</nct_id>
  </id_info>
  <brief_title>Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?</brief_title>
  <acronym>FLAIR</acronym>
  <official_title>Evaluation of the Correlation Between the MS Functional Composite Index and Two Quality of Life Scales (MS54 and AMS Quality of Life) in Relapsing MS Patients Treated With Interferon Beta-1a (AVONEX®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was to find out if patients with Relapsing Remitting Multiple Sclerosis treated&#xD;
      with Interferon beta-1a had an improved quality of life after treatment with Interferon&#xD;
      beta-1a&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was an open-label, multi-center, international post-marketing study (phase 4).&#xD;
      Eligible patients were interferon naïve patients suffering from relapsing MS. The duration of&#xD;
      a subject's participation in the study was up to a maximum 26 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1999</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to evaluate the correlation between the MS Functional Composite Index and two Quality of Life scales (MS Quality of Life 54 and AMS Quality of Life) in patients treated with interferon beta-1a (AVONEX®).</measure>
    <time_frame>screening, Day -30, Day -1, Months 3, 6, 12, 18, and 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reproducibility of Quality of Life scales per language version</measure>
    <time_frame>months 18 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reliability of the Quality of Life scales per language version</measure>
    <time_frame>months 18 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EDSS score throughout the study</measure>
    <time_frame>screening, Day -1, Months 12 and 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">284</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients received Avonex IM injections and be evaluated for quality of life criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta-1a</intervention_name>
    <description>IM injection</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Relapsing Remitting Multiple Sclerosis&#xD;
&#xD;
          -  Interferon naïve&#xD;
&#xD;
          -  Eligible for interferon beta-1a (AVONEX®) therapy as per Summary of Product&#xD;
             Characteristics:&#xD;
&#xD;
          -  Subject has had relapsing MS for &gt; 1 year&#xD;
&#xD;
          -  Subject has had experienced 2 exacerbations in the last 2 years&#xD;
&#xD;
          -  Subject had an EDSS [5] score of &lt; 5.5&#xD;
&#xD;
          -  Subject was ambulant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of MS defined as progressive&#xD;
&#xD;
          -  History of any significant cardiac, hepatic, pulmonary, or renal disease; immune&#xD;
             deficiency; or other medical conditions that would preclude therapy with interferon&#xD;
             beta&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions or history of hypersensitivity to&#xD;
             human albumin&#xD;
&#xD;
          -  History of seizures within the 3 months prior to starting this study&#xD;
&#xD;
          -  History of intolerance to acetaminophen (paracetamol), ibuprofen, naproxen or other&#xD;
             NSAIDs, that would preclude use of at least one of these during the study&#xD;
&#xD;
          -  History of intolerance to interferons&#xD;
&#xD;
          -  Previous use of interferon beta&#xD;
&#xD;
          -  Female subjects who were pregnant or breast-feeding&#xD;
&#xD;
          -  For female subjects, unless postmenopausal or surgically sterile, unwillingness to&#xD;
             practice effective contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biogen-Idec Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>neurologyclinicaltrials@biogenidec.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Sijsele-Damme</city>
        <zip>8340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Esch-Sur-Alzette</city>
        <zip>4011</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Luxembourg</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>September 21, 2007</study_first_submitted>
  <study_first_submitted_qc>September 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2007</study_first_posted>
  <last_update_submitted>December 11, 2007</last_update_submitted>
  <last_update_submitted_qc>December 11, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2007</last_update_posted>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Avonex</keyword>
  <keyword>Interferon beta-1a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

